Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?

Apr 21 2017

• By Emily Hayes

Cholesterol plaque in artery

Related Content

Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?

Mar 18 2017

Amgen's Statin Intolerance Study May Not Cure What Ails PCSK9 Inhibitors

Apr 04 2016

Esperion Says FDA Stance Means No Clear Regulatory Path For ETC-1002

Jun 29 2016

Esperion Says FDA On Board With Filing Strategy For Bempedoic Acid

Mar 20 2017

Will Physician Demand For Repatha Put Pressure On Payer Restrictions?

Mar 20 2017

Amgen Says Repatha Outcomes Trial Backs Up Its Pricing Math

Mar 20 2017

Broad Enough? Sponsors Pleased With Narrower Praluent Label

Jul 24 2015

Praluent Panel To Focus On Indication Breadth Absent CV Outcomes Data

Jun 05 2015

<em>Praluent</em> Sponsors Set Tone For PCSK9 Labeling, Post-Marketing Negotiations

Jan 18 2016

Does Esperion's Plan For A Statin-Intolerant Claim Have A Shot?

Jan 25 2016

PCSK9 Inhibitors May Feel Effects Of FDA Judgment On IMPROVE-IT

Jan 25 2016

PCSK9 Revised Analysis Indicates Less Price Discounting May Be Needed

Oct 09 2015

Cholesterol Guidelines Look High And Low: Statin Market Extended At Both Ends

Nov 13 2013

Related Companies

Merck & Co., Inc.

Amgen, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Esperion Therapeutics, Inc.

Pfizer Inc.

Additional Topics

Reimbursement Clinical Trials Commercial Regulation Cardiovascular BioPharmaceutical

More from Cardiovascular

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window